Skip to content

A randomized controlled study for comparing the efficacy of hyperthermic intraperitoneal chemoperfusion (HIPEC) added in primary epithelial ovarian /fallopian tube carcinoma in primary exploration and interval debulking surgery (IDS) with conventional therapy

A randomized controlled study for comparing the efficacy of hyperthermic intraperitoneal chemoperfusion (HIPEC) added in primary epithelial ovarian /fallopian tube carcinoma in primary exploration and interval debulking surgery (IDS) with conventional therapy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000028894
Enrollment
Unknown
Registered
2020-01-06
Start date
2020-01-20
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary epithelial ovarian/fallopian tube carcinoma

Interventions

experimental group:HIPEC was added in the initial exploration and interval debulking surgery(IDS)
control group:conventional therapy

Sponsors

Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years; 2. Primary epithelial/fallopian tube cancer was confirmed pathologically and estimated to be stage III~IV by preoperative imaging; 3. Untreated primary patients; 4. ECOG score 0-2; 5. Initial probe FOGOTTI score >= 6 points, unable to achieve satisfactory PDS; 6. WBC >= 4.0 x 10^9/L, hemoglobin >= 80g/L, platelet >= 80.0 x 10^9/L (after correction); Serum bilirubin <= normal upper limit, ALT and AST <= normal upper limit; Urea nitrogen (BUN) <= the upper limit of normal value, creatinine (Cr)<= the upper limit of normal value; 7. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Have a history of other malignant tumor diseases (except thyroid cancer) or have received anti-tumor treatment (including chemotherapy, radiotherapy and surgery); 2. Severe uncontrolled internal or surgical disease or acute infection; 3. Female patients who are pregnant or breastfeeding; 4. Gastrointestinal bleeding, perforation, intestinal obstruction or history of related diseases; 5. Extensive adhesion in the pelvic cavity; 6. All the treatments could not be completed in our hospital due to distance.

Design outcomes

Primary

MeasureTime frame
5-year overall survival;

Secondary

MeasureTime frame
The 5-year disease-free survival rate (PFS); 2 - year OS and PFS ;changes in tumor load score at the initial exploration and IDS between the two groups, surgical satisfaction rate of IDS, and platinum-free interphase.;comparison of grade 3-4 adverse events and quality of life;

Countries

China

Contacts

Public ContactFeng Weiwei

Department of Obstetrics and Gynecology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine

wfeng7347@aliyun.com+86 18917763870

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026